Drug intelligence / Profile preview

EF-465

Development stage: Preclinical
Lead developer: EditForce
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

EF-465 is a discovery-stage RNA editing therapeutic being developed by EditForce. The program utilizes EditForce's proprietary Pentatricopeptide Repeat (PPR) protein platform, which enables sequence-specific recognition and binding to RNA molecules. EF-465 is currently being investigated for the treatment of neuronal and cardiac diseases. The therapeutic mechanism involves site-specific RNA modification to address genetic mutations or protein expression imbalances, though the specific molecular targets for this program have not been publicly disclosed.

Beyond the preview

Go deeper on EF-465.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EF-465.

Explore the full profile